Indole Derivatives for PBR Imaging Brain Uptake
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current in vivo imaging agents for the peripheral benzodiazepine receptor (PBR) have limitations such as low brain uptake and specific binding, which hampers effective imaging for conditions associated with abnormal PBR expression.
Innovation Solution
A novel tricyclic indole compound is developed as an in vivo imaging agent with improved brain uptake and specificity for the PBR, utilizing a precursor compound for synthesis and a radiopharmaceutical composition suitable for PET imaging.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If existing in vivo imaging agents are used for PBR imaging, then the imaging can be performed, but the brain uptake and specific binding are insufficient
Solution Approach 1:
The patent modifies the chemical structure of indole-based imaging agents by changing parameters such as substituting aromatic rings with carbazole rings, adding functional groups (e.g., carboxylic acid, amide), and adjusting molecular weight and lipophilicity. These parameter changes optimize both brain uptake and specific binding to PBR simultaneously.
Solution Approach 2:
The invention creates composite molecular structures combining carbazole core with various functional groups and substituents (e.g., carboxylic acid, amide, hydroxyl groups). These composite structures leverage the high affinity of carbazole for PBR while the functional groups enhance brain uptake through improved pharmacokinetic properties.
2Reliability
If existing imaging agents are used, then PBR binding is achieved, but the imaging effectiveness for neurodegenerative diseases is limited
Solution Approach 1:
The patent introduces functional groups at specific local positions on the indole/carbazole molecule to optimize interaction with PBR. For example, carboxylic acid groups at certain positions enhance binding affinity, while hydroxyl groups at other positions improve brain uptake. This localized optimization ensures both high specific binding and imaging effectiveness.
Solution Approach 2:
The invention systematically changes molecular parameters including molecular weight, logP (lipophilicity), and functional group composition to achieve optimal balance between brain penetration and PBR binding. These parameter adjustments ensure reliable imaging effectiveness for detecting neurodegenerative diseases.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The new imaging agent provides enhanced brain uptake and specific binding to PBR, enabling more effective imaging of conditions related to abnormal PBR expression, such as neurodegenerative diseases and inflammatory disorders.
Implementation Method 1
a radiopharmaceutical composition comprising the in vivo imaging agent of the invention
Data Source
AI summary
An indole-based in vivo imaging agent is provided by the present invention that binds with high affinity to PBR, has good uptake into the brain following administration, and which has good selective binding to PBR. The invention also includes a precursor compound useful in the synthesis of the in vivo imaging agent of the invention, as well as a method for synthesis of said in vivo imaging agent comprising use of said precursor compound, and a kit for carrying out said method. Also provided is a cassette for automated synthesis of the in vivo imaging agent. Further aspects of the invention include a radiopharmaceutical composition comprising the in vivo imaging agent of the invention, and methods for the use of said in vivo imaging agent.